← TRAW
TRAW— Traws Pharma, Inc.
MaterialsPharmaceutical Preparations
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.8M+1134.5% | $226K+0.0% | $226K+0.0% | $226K+0.0% | $226K-2.2% | $231K |
| Acquired in-process research and development | $117.5M | — | — | — | — | — |
| Research and development | $12.1M-5.5% | $12.8M+12.4% | $11.4M+0.2% | $11.4M+56.3% | $7.3M-56.8% | $16.9M |
| General and administrative | $8.5M-30.7% | $12.3M+35.1% | $9.1M+7.7% | $8.4M-10.4% | $9.4M+13.2% | $8.3M |
| Total operating expenses | $20.7M-85.5% | $142.6M+594.8% | $20.5M+3.4% | $19.9M+18.7% | $16.7M-33.7% | $25.2M |
| Loss from operations | -$17.9M+87.4% | -$142.4M-601.4% | -$20.3M-3.4% | -$19.6M-19.0% | -$16.5M+34.0% | -$25.0M |
| Change in fair value of warrant liability /Series A warrant and pre-funded warrant expense | $26.6M+208.7% | -$24.4M | — | — | — | -$208K |
| Other income, net | $478K+65.4% | $289K-78.6% | $1.4M+103.6% | $663K+5425.0% | $12K-75.0% | $48K |
| Net income (loss) | $9.2M+105.5% | -$166.5M-778.8% | -$18.9M | — | — | — |
| Net income (loss) attributable to common stockholders, basic | $6.9M+112.6% | -$54.7M-188.5% | -$18.9M | — | — | — |
| Net income (loss) attributable to common stockholders, diluted | $6.9M+112.6% | -$54.7M-188.5% | -$18.9M | — | — | — |
| Weighted-average shares of common stock outstanding, basic (in shares) | $8.2M+429.9% | $1.6M+84.9% | $840K-96.0% | $20.9M+24.2% | $16.8M+45.1% | $11.6M |
| Net income (loss) per share of common stock, basic (in dollars per share) | $0.83+102.4% | -$35.21-56.0% | -$22.57-2380.2% | -$0.91+5.2% | -$0.96+55.8% | -$2.17 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | $8.4M+439.5% | $1.6M+84.9% | $840K-96.0% | $20.9M+24.2% | $16.8M+45.1% | $11.6M |
| Net income (loss) per share of common stock, diluted (in dollars per share) | $0.82+102.3% | -$35.21-56.0% | -$22.57-2380.2% | -$0.91+5.2% | -$0.96+55.8% | -$2.17 |
| Net income (loss) attributable to Series C Preferred stockholders, basic | $2.3M+102.1% | -$111.8M | — | — | — | — |
| Net income (loss) attributable to Series C Preferred stockholders, diluted | $2.3M+102.1% | -$111.8M | — | — | — | — |
| Weighted-average shares of Series C Preferred outstanding, basic (in shares) | $7K-13.0% | $8K | — | — | — | — |
| Weighted-average shares of Series C Preferred outstanding, diluted (in shares) | $7K-13.0% | $8K | — | — | — | — |
| Net income (loss) per share of Series C Preferred, basic (in dollars per share) | $333.77+102.4% | -$14K | — | — | — | — |
| Net income (loss) per share of Series C Preferred, diluted (in dollars per share) | $333.77+102.4% | -$14K | — | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.